Company news
SciSparc Ltd. news in 2023
SciSparc Ltd.'s news releases, calls and decks from 2023, newest first.
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
December 12, 2023
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
December 6, 2023
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
November 27, 2023
SciSparc Adopts Limited Duration Shareholder Rights Plan
November 27, 2023
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
November 21, 2023
SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
November 9, 2023
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
October 30, 2023
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
October 23, 2023
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
October 12, 2023
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
October 10, 2023
SciSparc Granted European Patent for its Core Technology
October 2, 2023
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
September 28, 2023
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
September 26, 2023
SciSparc Announces 1-for-26 Reverse Share Split
September 19, 2023
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
September 11, 2023
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
September 6, 2023
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
August 13, 2023
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
August 9, 2023
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
August 8, 2023
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
July 31, 2023
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
July 13, 2023
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
June 29, 2023
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
June 20, 2023
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
June 6, 2023
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
June 1, 2023
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
May 29, 2023
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
May 1, 2023
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
April 3, 2023
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
March 27, 2023
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
March 8, 2023
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
March 5, 2023
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
February 26, 2023
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
February 22, 2023
SciSparc Announces Corporate Restructuring plan
January 24, 2023
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
January 17, 2023
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
January 16, 2023
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
January 8, 2023
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
January 4, 2023
Decks in 2023
- Investor Presentation (October 2023)
Investor deck · 23 slides · Oct 18, 2023